Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

NCT06629584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Tumors

Interventions

DRUG: Asciminib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]